Gemcitabine (1000 mg/m2)

DRUG5 trials

Sponsors

SciClone Pharmaceuticals, Fudan University, National Cancer Institute, Egypt, Hospital Universitario Dr. Jose E. Gonzalez, Peking University First Hospital

Conditions

Diffuse Pleural Mesothelioma (DPM)Pancreatic CancerRelapsed/Refractory Diffuse Large B Cell LymphomaUpper Tract Urothelial Carcinoma

Phase 2

Phase II Study to Evaluate Efficacy and Safety of RP101 in Combination With Gemcitabine

TerminatedNCT00550004

SciClone PharmaceuticalsPancreatic Cancer

Start: 2007-09-30End: 2009-10-31Target: 153Updated: 2011-06-08

Gemcitabine as Maintenance Treatment for Diffuse Pleural Mesothelioma

CompletedNCT07411144

National Cancer Institute, EgyptDiffuse Pleural Mesothelioma (DPM)

Start: 2020-03-15End: 2023-03-15Updated: 2026-02-13

Low Dose Epcoritamab Plus GemOx in R/R DLBCL

RecruitingNCT07451652

Hospital Universitario Dr. Jose E. GonzalezRelapsed/Refractory Diffuse Large B Cell Lymphoma

Start: 2026-03-17End: 2027-09-01Target: 10Updated: 2026-04-01

Disitamab Vedotin Plus Radiotherapy for Adjuvant Treatment of HER2-Expressing Cisplatin-Ineligible Upper Tract Urothelial Carcinoma

Not yet recruitingNCT07498907

Peking University First HospitalUpper Tract Urothelial Carcinoma

Start: 2026-05-01End: 2034-03-01Target: 192Updated: 2026-03-27

Phase 3

Active Anti-diabetic Treatment Plus Chemotherapy for Pancreatic Cancer Related Diabetes

Not yet recruitingNCT07272109

Fudan UniversityPancreatic Cancer

Start: 2026-01-01End: 2028-12-30Target: 210Updated: 2025-12-15

Related Papers

Gemcitabine as maintenance treatment of diffuse pleural mesothelioma: randomized phase II study

BMC Cancer2026-03-26

RP101 (brivudine) binds to heat shock protein HSP27 (HSPB1) and enhances survival in animals and pancreatic cancer patients.

2011-07-2271 citations